Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion to Expand JAK Inhibitor Portfolio in Myeloproliferative Neoplasms
Eli Lilly and Company (NYSE: LLY) and Ajax Therapeutics, Inc. announced a definitive agreement on...
Others
Bio-Thera Solutions Reports 25.84% Revenue Growth in 2025 Driven by Biosimilar Portfolio Expansion and US Market Entry
Bio-Thera Solutions Ltd. (SHA: 688177) announced its financial results for fiscal year 2025, reporting revenues...
Sun Pharma to Acquire Organon for $11.75 Billion, Creating Global Top-25 Pharmaceutical Leader in Branded Generics
Sun Pharmaceutical Industries Ltd (NSE: SUNPHARMA) announced a definitive agreement to acquire Organon & Co....
China’s National Health Commission Proposes Sweeping Reforms to Narcotics and Psychotropic Drugs Management Framework
China’s National Health Commission (NHC) released a draft notification for public consultation on comprehensive revisions...
China’s Drug Quality Control System Shows 99.5% Compliance Rate in 2025 NMPA Report
The National Medical Products Administration (NMPA) has released its National Drug Sampling Inspection Annual Report...
Bayer AG Secures NMPA Approval for Hyrnuo (Sevabertinib) to Treat HER2-Mutant NSCLC in China
Bayer AG (ETR: BAYN) announced that China’s National Medical Products Administration (NMPA) has granted marketing...
Nanjing Pharma Launches $110M Corporate Fund to Acquire Controlling Stakes in Datsing Bio and Kejian Tech
Nanjing Pharmaceutical Group Co., Ltd. (SHA: 600713) has unveiled a strategic plan to establish a...
Ascletis Pharma Advances Oral GLP-1R/Amylin Receptor Dual Agonist Combination ASC30/ASC39 for Obesity, Targeting Q3 FDA IND Submission
Ascletis Pharma Inc. (HKG: 1672) announced the selection of a fixed-dose combination (FDC) of ASC30...
Basecare Medical Secures NMPA Category III Approval for Gems Series IVF Culture Media, Expanding China’s Domestic Embryo Culture Solutions
Suzhou Basecare Medical Co., Ltd (HKG: 2170), a China-based in vitro fertilization (IVF) specialist, announced...
Insilico Medicine Advances AI-Discovered NR3C1 Antagonist ISM6200 into Clinical Development for Ovarian Cancer and Cortisol-Excess Disorders
Insilico Medicine (HKG: 3696), a China-based artificial intelligence drug discovery platform, announced the selection of...
Shanghai Huilun Pharma Launches Hong Kong IPO with Integrated Pharmaceutical Platform and Robust Pipeline
Shanghai Huilun Pharmaceutical Co., Ltd. has successfully completed its initial public offering (IPO) on the...
Staidson Pharma Announces $182M Private Placement to Advance Innovative Biologics Pipeline
Staidson (Beijing) Pharmaceutical Co., Ltd. (SHE: 300204) announced plans to raise up to RMB 1.253...
China’s NMPA Unveils Ambitious “AI + Drug Regulation” Roadmap Through 2035
China’s National Medical Products Administration (NMPA) today released its comprehensive “Implementation Opinions on ‘AI +...
Boehringer Ingelheim 2024 Revenue EUR 27.8B – Jardiance Drives 8.7% Growth, R&D Intensity Hits 22.9%
Boehringer Ingelheim reported 2024 financial results, with group net sales rising 7.3% YoY to EUR...
Gilead to Acquire Ouro Medicines for $2.175 Billion – Keymed Biosciences Secures $320 Million from CM336 TCE Deal
Keymed Biosciences Inc. (HKG: 2162) announced that its NewCo partner Ouro Medicines has entered into...
Luzhu Biotechnology Reports 2025 Results – LZ901 Shingles Vaccine Nears Commercialization with Shingrix‑Beating Data
Luzhu Biotechnology (HKG: 2480) announced its audited 2025 annual results, highlighting significant progress toward LZ901...
Simcere Pharma Reports Positive SIM0237 Phase I/II Data – 80% CR Rate in BCG‑Unresponsive Bladder Cancer
Simcere Pharmaceutical Group Limited (HKG: 2096) announced positive Phase I/II results for SIM0237, its PD‑L1/IL‑15...
Shanghai Pharmaceuticals and Henlius Forge Strategic Alliance – Hospital Market Expansion and Global Commercial Collaboration Targeted
Shanghai Pharmaceuticals Holding Co., Ltd. (SPH; HKG: 2607, SHA: 601607) and Henlius (HKG: 2696) announced...
MSD’s Prevymis Wins NMPA Approval for 200‑Day Pediatric CMV Prophylaxis – Extended Post‑Transplant Protection
Merck & Co. (MSD, NYSE: MRK) announced that Prevymis (letermovir), its novel non‑nucleoside cytomegalovirus (CMV) inhibitor,...
Trinomab’s Retavibart NDA Accepted by NMPA – First Long‑Acting RSV mAb for Infant Protection in China
Zhuhai Trinomab Biopharmaceutical Co., Ltd. announced that China’s National Medical Products Administration (NMPA) has accepted...